LRIG1 Protein, Mouse, Recombinant (His)

SKU TMPY-02264-50 μg Category Recombinant-Protein Brand: TargetMol

Price range: 440 CAD through 2,864 CAD

Size

50 μg 500 μg

Clear

Products Details

Product Description

– Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases. Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit the growth of different types of malignancies. Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein, which is induced by epidermal growth factor (EGF) and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– TMPY-02264

Storage Temperature

– -20℃

Shipping

– Blue Ice

References

– Shattuck DL,et al.(2007) LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy. Mol Cell Biol. 27 (5): 1934-46.

Molecular Weight

Product type

– Recombinant-Protein

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.